Overview Dividends

(MDGL) Madrigal Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5588681057

Rezdiffra, Liver Therapy, MASH Treatment, Thyroid Agonist

Biotechnology
Market Cap in USD: 13,488m
IPO / Inception: 2007-02-06
Return 12m vs S&P 500: 48.0%

EPS (Earnings per Share)

EPS (Earnings per Share) of MDGL over the last years for every Quarter: "2020-12": -3.82, "2021-03": -3.32, "2021-06": -3.72, "2021-09": -3.79, "2021-12": -3.78, "2022-03": -3.36, "2022-06": -4.14, "2022-09": -4.75, "2022-12": -4.98, "2023-03": -4.23, "2023-06": -4.69, "2023-09": -5.34, "2023-12": -5.68, "2024-03": -7.38, "2024-06": -7.1, "2024-09": -4.92, "2024-12": -2.71, "2025-03": -3.32, "2025-06": -1.9, "2025-09": -4.9555, "2025-12": 0,
EPS CAGR: 16.06%
EPS Trend: 45.3%
Last SUE: 0.42
Qual. Beats: 0

Revenue

Revenue of MDGL over the last years for every Quarter: 2020-12: 0, 2021-03: 0.273, 2021-06: 0.01011, 2021-09: 0.008287, 2021-12: 3.732E-5, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0.77, 2024-03: 0, 2024-06: 14.638, 2024-09: 62.175, 2024-12: 103.32, 2025-03: 137.25, 2025-06: 212.802, 2025-09: 287.268, 2025-12: null,
Rev. CAGR: 6760.55%
Rev. Trend: 87.8%
Last SUE: 2.18
Qual. Beats: 3

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 60.4%
Value at Risk 5%th 90.4%
Relative Tail Risk -9.01%
Reward TTM
Sharpe Ratio 1.26
Alpha 60.52
CAGR/Max DD 0.38
Character TTM
Hurst Exponent 0.513
Beta 0.845
Beta Downside 0.688
Drawdowns 3y
Max DD 61.41%
Mean DD 18.77%
Median DD 16.67%

Description: MDGL Madrigal Pharmaceuticals November 06, 2025

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is a U.S.-based biopharma focused on treating metabolic dysfunction-associated steatohepatitis (MASH). Its lead asset, Rezdiffra, is a liver-targeted thyroid hormone receptor-β agonist designed to reduce liver fat and inflammation in MASH patients. The company is headquartered in West Conshohocken, Pennsylvania, and trades as a common stock in the Biotechnology sub-industry.

As of the latest quarter (Q3 2024), Madrigal reported roughly $210 million of cash and marketable securities, giving it an estimated 12-month runway at current burn rates. Phase 2b data for Rezdiffra showed a statistically significant reduction in liver fat content (-15 % vs. placebo) and favorable safety signals, positioning the program for a potential Phase 3 launch in 2025. The U.S. MASH market is projected to exceed $10 billion by 2028, driven by rising obesity and type-2 diabetes prevalence, while the broader biotech sector is experiencing a 7 % annual revenue growth rate, supported by strong venture capital inflows and accelerated FDA review pathways for liver diseases.

For a deeper dive into Madrigal’s financial outlook and competitive positioning, you may find ValueRay’s analyst notes useful as a next step in your research.

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (-289.1m TTM) > 0 and > 6% of Revenue (6% = 44.4m TTM)
FCFTA -0.12 (>2.0%) and ΔFCFTA 28.98pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 129.0% (prev 1142 %; Δ -1013 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.12 (>3.0%) and CFO -160.6m > Net Income -289.1m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 3.44 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (22.5m) change vs 12m ago 3.39% (target <= -2.0% for YES)
Gross Margin 95.25% (prev 96.01%; Δ -0.75pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 60.81% (prev 7.23%; Δ 53.59pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -15.51 (EBITDA TTM -270.1m / Interest Expense TTM 17.5m) >= 6 (WARN >= 3)

Altman Z'' -4.66

(A) 0.70 = (Total Current Assets 1.35b - Total Current Liabilities 391.4m) / Total Assets 1.36b
(B) -1.49 = Retained Earnings (Balance) -2.03b / Total Assets 1.36b
warn (B) unusual magnitude: -1.49 — check mapping/units
(C) -0.22 = EBIT TTM -271.6m / Avg Total Assets 1.22b
(D) -2.76 = Book Value of Equity -2.03b / Total Liabilities 736.7m
Total Rating: -4.66 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 57.07

1. Piotroski 1.50pt
2. FCF Yield -1.27%
3. FCF Margin -21.82%
4. Debt/Equity 0.55
5. Debt/Ebitda -0.19
6. ROIC - WACC (= 186.9)%
7. RoE -41.50%
8. Rev. Trend 87.81%
9. EPS Trend 45.33%

What is the price of MDGL shares?

As of January 07, 2026, the stock is trading at USD 558.01 with a total of 732,348 shares traded.
Over the past week, the price has changed by -4.41%, over one month by -1.86%, over three months by +26.16% and over the past year by +73.94%.

Is MDGL a buy, sell or hold?

Madrigal Pharmaceuticals has received a consensus analysts rating of 4.47. Therefore, it is recommended to buy MDGL.
  • Strong Buy: 10
  • Buy: 3
  • Hold: 1
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the MDGL price?

Issuer Target Up/Down from current
Wallstreet Target Price 603.5 8.1%
Analysts Target Price 603.5 8.1%
ValueRay Target Price 700 25.5%

MDGL Fundamental Data Overview January 05, 2026

Market Cap USD = 13.49b (13.49b USD * 1.0 USD.USD)
P/E Forward = 666.6667
P/S = 18.2108
P/B = 21.555
Beta = -1.046
Revenue TTM = 740.6m USD
EBIT TTM = -271.6m USD
EBITDA TTM = -270.1m USD
Long Term Debt = 339.8m USD (from longTermDebt, last quarter)
Short Term Debt = 1.08m USD (from shortTermDebt, last quarter)
Debt = 346.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 50.7m USD (from netDebt column, last quarter)
Enterprise Value = 12.72b USD (13.49b + Debt 346.4m - CCE 1.11b)
Interest Coverage Ratio = -15.51 (Ebit TTM -271.6m / Interest Expense TTM 17.5m)
FCF Yield = -1.27% (FCF TTM -161.6m / Enterprise Value 12.72b)
FCF Margin = -21.82% (FCF TTM -161.6m / Revenue TTM 740.6m)
Net Margin = -39.04% (Net Income TTM -289.1m / Revenue TTM 740.6m)
Gross Margin = 95.25% ((Revenue TTM 740.6m - Cost of Revenue TTM 35.1m) / Revenue TTM)
Gross Margin QoQ = 93.69% (prev 95.74%)
Tobins Q-Ratio = 9.34 (Enterprise Value 12.72b / Total Assets 1.36b)
Interest Expense / Debt = 2.15% (Interest Expense 7.45m / Debt 346.4m)
Taxrate = 100.0% (out of range, set to none) (-465.9m / -465.9m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 3.44 (Total Current Assets 1.35b / Total Current Liabilities 391.4m)
Debt / Equity = 0.55 (Debt 346.4m / totalStockholderEquity, last quarter 625.7m)
Debt / EBITDA = -0.19 (negative EBITDA) (Net Debt 50.7m / EBITDA -270.1m)
Debt / FCF = -0.31 (negative FCF - burning cash) (Net Debt 50.7m / FCF TTM -161.6m)
Total Stockholder Equity = 696.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -21.22% (Net Income -289.1m / Total Assets 1.36b)
RoE = -41.50% (Net Income TTM -289.1m / Total Stockholder Equity 696.7m)
RoCE = -26.21% (EBIT -271.6m / Capital Employed (Equity 696.7m + L.T.Debt 339.8m))
RoIC = 195.8% (negative operating profit) (EBIT -271.6m / (Assets 1.36b - Curr.Liab 391.4m - Cash 1.11b))
WACC = 8.90% (E(13.49b)/V(13.83b) * Re(9.13%) + (debt cost/tax rate unavailable))
Discount Rate = 9.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.66%
Fair Price DCF = unknown (Cash Flow -161.6m)
EPS Correlation: 45.33 | EPS CAGR: 16.06% | SUE: 0.42 | # QB: 0
Revenue Correlation: 87.81 | Revenue CAGR: 6761 % | SUE: 2.18 | # QB: 3
EPS next Quarter (2026-03-31): EPS=-0.72 | Chg30d=-0.938 | Revisions Net=-3 | Analysts=5
EPS next Year (2026-12-31): EPS=2.44 | Chg30d=-1.790 | Revisions Net=-3 | Growth EPS=+124.2% | Growth Revenue=+52.7%

Additional Sources for MDGL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle